MedTrace Logo

EXCEL Clinical Trial

NCT01205776 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1905

Last updated 2020-04-07

Study results available
· View outcomes & findings →

Summary

To establish the safety and efficacy of the commercially approved XIENCE Family Stent System (inclusive of XIENCE PRIME, XIENCE V, XIENCE Xpedition and XIENCE PRO \[for use outside the United States \[OUS\] only\]) in subjects with unprotected left main coronary artery disease by comparing to coronary artery bypass graft surgery.

Conditions

  • Chronic Coronary Occlusion
  • Unprotected Left Main Coronary Artery Disease
  • Stent Thrombosis
  • Vascular Disease
  • Myocardial Ischemia
  • Coronary Artery Stenosis
  • Coronary Disease
  • Coronary Artery Disease
  • Coronary Restenosis

Interventions

DEVICE

Percutaneous Coronary Intervention

Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS

PROCEDURE

CABG

Those patients receiving CABG

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Gregg W Stone, MD · Columbia University

  • Patrick W Serruys, MD · Erasmus Medical Center

  • Joseph Sabik, MD · Cleveland Clinical Main Campus

  • A. Pieter Kappetein, MD · Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-29
Primary Completion
2019-05-03
Completion
2019-06-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01205776 on ClinicalTrials.gov